Safety and efficacy of ultrasound ciliary plasty as a primary intervention in glaucoma patients

Magda A. Torky1,2, Yousif A Al Zafiri2, Sherein M. Hagras1, Abeer M. Khattab1, Rania M. Bassiouny1, Tharwat H. Mokbel1

1Department of Ophthalmology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
2Department of Ophthalmology, Dar AlShifa Hospital, Hawally City 30000, Kuwait

Correspondence to: Sherein M. Hagras. Ophthalmic Center, Faculty of Medicine, Mansoura University, Al-Gomohoria Street, Mansoura 35516, Egypt. shereinhagras@gmail.com

Received: 2018-10-02        Accepted: 2019-01-02

Abstract

• AIM: To evaluate the safety and the efficacy of the ultrasound ciliary plasty (UCP) on the intraocular pressure (IOP) control in glaucomatous eyes without previous glaucoma surgery.

• METHODS: A retrospective study included patients with primary and secondary glaucoma who underwent UCP in Dar AlShifa Hospital, Kuwait between January 2017 to June 2018. High-intensity focused ultrasound procedures were performed under peribulbar anesthesia using the 2nd generation probe with 8s duration of each of the 6 shots. Complete ophthalmologic examinations were scheduled pre-treatment, and at 1d, 1wk, 1, 3, 6 and 12mo post-treatment. Primary outcomes were the IOP reduction and success rates at 12mo, while the secondary outcomes were the occurrence of vision threatening complications and visual acuity.

• RESULTS: The records of 62 eyes of 62 patients were analyzed with mean age of 63.8y (67.7% males). There was statistically significant reduction in the mean IOP from 35.2±8.3 mm Hg before treatment to 20.6±8.7 mm Hg at 12th month (P<0.0005) with a mean percentage IOP reduction of 42.3% with significant reduction in the mean number of antiglaucomatous drugs from 3.2±0.4 before treatment to 2.1±1.02 at 12mo (P<0.0005). Qualified success was achieved in 77.4% of eyes at 12mo. No major intra- or post-treatment complications were reported.

• CONCLUSION: Second-generation UCP prove to be effective in reducing IOP in naive glaucoma patients with lower success rates in cases of neovascular and uveitic glaucomas.

• KEYWORDS: ultrasound ciliary plasty; glaucoma; intraocular pressure

DOI:10.18240/ijo.2019.04.12


INTRODUCTION

Cyclodestructive procedures had been widely considered as the last option for management of uncontrolled glaucoma after failure of all standard lines[1]. These modalities had proved to achieve encouraging intraocular pressure (IOP) lowering abilities over the past decades. However, concerns regarding their probable side effects as their non-selective action over the target tissues and the arbitrary dose-effect correlation had often compelled surgeons to save them for eyes with advanced and end-stage glaucoma[2].

High-intensity focused ultrasound technology (HIFU) had been advocated formerly in 1980s as a relatively safe alternative modality for ciliary body ablation[3]. However, it was abandoned owing to its complexity and the drawbacks encountered by the procedure[4]. Several technical adjustments with substantial modifications in the procedure had reintroduced it as a novel approach for cyclodestruction[5].

Ultrasound ciliary plasty (UCP) permits a precise thermal action over the target tissues causing less collateral damage to adjacent tissues while treating non-optically transparent structures[6]. Recently, published studies reported encouraging results of UCP in patients with refractory glaucoma regarding both safety and efficacy[7-9]. These results had favored the extension of UCP indication to include glaucoma patients who were not operated before[10].

Though proposed, the use of UCP as a primary treatment of glaucoma is still not widely studied. The main objective of the current study was to evaluate the safety and efficacy of UCP in patients with medically uncontrolled glaucoma with different etiologies.
to June 2018. The study followed the tenets of the Declaration of Helsinki and was approved by local Institutional Review Board. Written informed consent was obtained from all the enrolled patients.

Adult patients (>18y) with moderate to advanced primary or secondary glaucoma without previous incisional glaucoma surgery were included in this study. Patients were enrolled if they had uncontrolled IOP [defined as IOP >21 mm Hg despite maximal tolerated antiglaucomatous drugs (AGD)] and presented with a contraindication to glaucoma invasive surgery. Only records of patients who completed the 12mo’ follow-up period were counted in. Patients were excluded from the study if they were diagnosed with normal tension glaucoma or had intraocular surgery (apart from cataract extraction) or laser treatment within 3mo before UCP therapy, or had previous cyclo-destructive procedure as well as patients diagnosed with ocular infection within 2wk before UCP. Records of patients with glaucoma surgical intervention within less than 12mo after UCP treatment were not included in the study.

Data pertaining to patient demographics as well as glaucoma diagnosis were retrieved. In addition, the following data were recorded before and after UCP therapy: best-corrected visual acuity using (BCVA) Snellen’s chart converted to logMAR for statistical analysis, slit-lamp biomicroscopy with gonioscopy, dilated fundus examination and Goldmann applanation tonometry (3 readings). Pretreatment investigations comprised: white-to-white measurement of the corneal diameter and axial length measurements by IOL Master 500 (Carl Zeiss Meditec AG., Germany), ultrasound pachymetry with Tomey SP-100 (Tomey Corp. Nagoya, Japan) and visual fields using Humphrey Field Analyzer (24-2, SITA, standard program Carl Zeiss Meditec AG., Germany).

Procedure High-intensity focused ultrasound procedures were performed by 2 authors under peribulbar anesthesia. After lying in supine position; the coupling cone was first adjusted on the center of the patient’s eye and kept in place via low vacuum suction. The treatment probe was then introduced inside the cone, and the transducers were consecutively automatically being activated by constant pressing over the foot switch. In the current study, the 2nd generation probe was used in all the cases (EyeOP1, Eye Tech care; France). The following parameters were used for all treatments: operating frequency, 21 MHz; number of sectors activated, 6; acoustic power, 2.45 W; duration of each shot, 8s; and time between each shot, 20s. Choice of the probe diameter (11, 12 or 13 mm) was based on the patient’s eye biometric readings. More details about the procedure are available in the video article by Giannaccare et al [11].

Follow-up visits were scheduled at 1d, 1wk, 1, 3, 6, 9 and 12mo. Preoperative AGD were maintained unchanged during the first month after treatment after which it was adapted whenever necessary. In addition to the pressure-lowering drugs; postoperative combination of dexamethasone and tobramycin (Tobradex; Alcon Laboratories, Inc., Fort Worth, TX, USA) was given 4 times daily for 1mo followed by gradual withdrawal.

Outcome Measures Primary outcomes were the reduction of the IOP and success rates at the end of the follow-up period, while the secondary outcomes were the report of intra- or postoperative complications and visual acuity.

Success and failure rates: qualified success was defined as IOP >5 mm Hg and reduction by ≥30% from baseline values with or without AGD. Failure was considered whenever IOP reduction was <30% despite the use of AGD or the development of any devastating complications or the need of other glaucoma surgeries.

Statistical Analysis Data were analyzed by Statistical Package of Social Science (SPSS; Chicago, USA, version 16). Normalization of data was tested with Shapiro-Wilk test. Categorical variables were represented with number and percent and compared with Chi-square test. Continuous variables were represented in mean±SD for parametric data and median (range) for non-parametric variables. Paired t-test was used to compare parametric data while Wilcoxon Signed-Rank test was used to compare non-parametric ones.

RESULTS

Demographics A total of 78 records for 74 patients were retrieved and evaluated. The records of 62 eyes of 62 patients fulfilled the inclusion criteria and were included in the study. The mean age was 63.8y with 67.7% males. All patients had at least 12mo follow up period with mean of 13.6±1.4mo. Neovascular glaucoma was the most frequent diagnosis accounted for 24.2% of the treated eyes followed by primary open angle glaucoma (POAG) representing 21%. All the patients were receiving the maximal tolerated AGD (mean=3.2). Patient’s demographic and baseline clinical data are given in details in Table 1.

Efficacy For the entire included eyes, the mean IOP showed statistically significant reduction from 35.2±8.3 mm Hg before treatment to 20.6±8.7 mm Hg at 12th month (P<0.0005) with a mean percentage IOP reduction of 42.3% (SD=16.7) corresponding to mean IOP reduction of 14.5±6.6 mm Hg (range 3-28 mm Hg). Figure 1 illustrates the scatter-gram plot for the pretreatment versus post-treatment IOP at 12mo.

Table 2 summarizes the mean IOP reductions from baseline values along the follow-up points with the percent of qualified success at each point. There was statistically significant reduction in the IOP all over the follow-up points (P<0.0005). Qualified success was achieved in 77.4% of eyes (48/62) at the last follow-up.

The curve displayed in Figure 2 represents the mean IOP in all patients over the follow-up time. There was significant
reduction in the IOP at 1st day after treatment followed by rise over the next 3mo. This was pursued by fairly stable IOP till the end of the follow-up.

The mean number of topical AGD decreased significantly from 3.2±0.4 before treatment to 2.1±1.02 at 12mo (P<0.0005).

Table 1 Demographic and baseline clinical characteristics of the studied patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>63.8±10.4 (42-82)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>42 (67.7)</td>
</tr>
<tr>
<td>Female</td>
<td>20 (32.3)</td>
</tr>
<tr>
<td>Type of glaucoma, n (%)</td>
<td></td>
</tr>
<tr>
<td>Primary glaucoma</td>
<td></td>
</tr>
<tr>
<td>POAG</td>
<td>13 (21)</td>
</tr>
<tr>
<td>CACG</td>
<td>10 (16.1)</td>
</tr>
<tr>
<td>Secondary glaucoma</td>
<td></td>
</tr>
<tr>
<td>NVG</td>
<td>15 (24.2)</td>
</tr>
<tr>
<td>Uveitic</td>
<td>11 (17.7)</td>
</tr>
<tr>
<td>Pseudoexfoliative glaucoma</td>
<td>4 (6.5)</td>
</tr>
<tr>
<td>Others</td>
<td>9 (14.5)</td>
</tr>
<tr>
<td>Lens status, n (%)</td>
<td></td>
</tr>
<tr>
<td>Phakic</td>
<td>23 (37.1)</td>
</tr>
<tr>
<td>Pseudophakic</td>
<td>39 (62.9)</td>
</tr>
<tr>
<td>Pretreatment IOP (mm Hg)</td>
<td>35.2±8.3 (22-58)</td>
</tr>
<tr>
<td>No. of AGD</td>
<td>3.2±0.4 (3-4)</td>
</tr>
<tr>
<td>Follow-up period (mo)</td>
<td>13.6±1.4 (12-17)</td>
</tr>
<tr>
<td>LogMAR BCVA</td>
<td>0.72±0.23 (0.4-1.2)</td>
</tr>
</tbody>
</table>

SD: Standard deviation; POAG: Primary open angle glaucoma; NVG: Neovascular glaucoma; CACG: Chronic angle-closure glaucoma; IOP: Intraocular pressure; AGD: Anti-glaucomatous drugs; BCVA: Best corrected visual acuity.

Table 2 IOP reductions and qualified success along the follow-up period of the included patients

<table>
<thead>
<tr>
<th>Time</th>
<th>IOP (mm Hg)</th>
<th>IOP reduction (%)</th>
<th>Qualified success, n (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>35.2±8.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1st day</td>
<td>11.15±0.22</td>
<td>67.4±5.6</td>
<td>62 (100)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>1st week</td>
<td>12.05±0.23</td>
<td>64.5±7</td>
<td>62 (100)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>1st month</td>
<td>13.08±0.3</td>
<td>61.5±8.3</td>
<td>62 (100)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>3rd month</td>
<td>19.05±0.43</td>
<td>44.2±11.5</td>
<td>56 (90.3)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>6th month</td>
<td>18.07±0.64</td>
<td>48.2±10.6</td>
<td>59 (95.2)</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>12th month</td>
<td>20.6±8.7</td>
<td>42.3±16.7</td>
<td>48 (77.4)</td>
<td>&lt;0.0005</td>
</tr>
</tbody>
</table>

IOP: Intraocular pressure; SD: Standard deviation. P value denotes significance of the difference of the IOP at each follow-up point compared to the baseline value; test used Wilcoxon Signed-Rank test. Significance at P<0.05.

Figure 1 Scatter gram plot for IOP before treatment (X axis) and IOP at 12mo after treatment (Y axis) All the points below the diagonal dashed lines represent eyes with IOP reduction ≥30% from the baseline values.

Figure 2 Means of IOP of the included eyes at baseline and at different points along the follow-up period.

Figure 3 Success rates among different categories of glaucoma included in the study POAG: Primary open angle glaucoma; CACG: Chronic angle-closure glaucoma; NVG: Neovascular glaucoma; PEX: Pseudoexfoliative glaucoma.
UCP as primary treatment in glaucoma

Visual Acuity  There was statistically insignificant change in the logMAR mean BCVA from baseline of 0.72±0.23 to 0.73±0.26 at 12mo’ post-treatment (P=0.6).

Safety

Intraoperative  All the patients tolerated well to the procedure. None of the cases encountered any complications during the treatment (Table 3).

Postoperative  None of the eyes developed hypotony (IOP ≤5 mm Hg), choroidal detachments or phthisis. IOP spikes were not recorded for any of the eyes. All the cases developed moderate anterior chamber reaction that was treated by topical steroids for 2wk. Three eyes (4.8%) developed transient macular edema resolved after 1st month under topical non-steroidal anti-inflammatory drugs with no impact on the final BCVA. Two cases (3.2%) presented with mydriasis that lasted till the end of the follow-up. Punctate keratitis was recorded in 6 eyes (9.8%). Of the 14 eyes with insufficient response to UCP, 4 patients required glaucoma surgery; one patient required diode laser cyclophotocoagulation (CPC), and 3 patients had Ahmed valve surgery. These secondary treatments were carried out after 12mo from the UCP treatment. Patients with earlier intervention before 12mo follow-up were not included in the study (Table 3).

DISCUSSION

UCP is considered a revolutionary step in cyclodestructive maneuvers involved in glaucoma treatment. The procedure incorporates the selective application of HIFU over the ciliary processes in a non-invasive, single-step, computer-supported method[6]. Various reports studied the efficacy and the safety of UCP in controlling IOP especially in patients with refractory glaucoma[7-9]. The current study was designed and conducted to assess the safety and efficacy of UCP for the first time among Kuwaiti patients with either primary or secondary glaucoma who were naïve to glaucoma surgeries. In total, 62 eyes of 62 patients were enrolled in the study retrospectively. All the patients had completed the 12mo’ follow-up period.

The enrolled eyes presented with moderate to severe stages of the disease. Accordingly, we chose the target IOP reduction to be equal to or higher than 30% from the baseline values, meeting the requirements of some clinical studies as “Advanced Glaucoma Intervention Study”. These studies recommended a relatively stringent IOP target in eyes with advanced glaucoma in attempt to impede further progression in their visual field defects. Target IOP reduction of 20% was commonly used in previous studies evaluating the role of UCP in glaucoma patients. Thus, it might be rather complicated while comparing our results to those obtained previously.

In our study, the mean percentage of IOP reduction at 12mo was 42.3% which was higher than that reported previously in earlier studies, with IOP reduction ranging from 30% to 38%[7-9,12]. In the current study, none of patients had a history of preceding glaucoma surgery, whereas the former studies included refractory glaucoma patients who had - at least- previously one failed filtration surgery. Thus, the mean pretreatment IOP in our study was higher than that reported in the earlier reports with resultant higher reduction rates. In this aspect, our study would be more correspondent to the 2 studies published by Aptel et al[10] and Deb-Joardar and Reddy[11,12] including patients naïve to filtration surgery. They noted 30% and 32.3% reduction in IOP at 12mo respectively. Nevertheless, their study comprised only open angle glaucoma (OAG) patients with mean pretreatment IOP of 28.2 and 23.5 mm Hg which were also far less than our baseline values (35.2±8.3 mm Hg).

Qualified success was achieved in 77.4% in our study. Scrutinizing the results of the different glaucoma categories included in our study revealed lower success rates in NVG and uveitic eyes (40% and 55.5% respectively). It was suggested that patients with secondary glaucoma with pre-existing lower trabecular meshwork outflow of aqueous humor would have suboptimal response to a decrease in aqueous production and thus induce poorer effect on IOP control[12]. In contrary, Giannaccare and associates[13] found a higher percentage of IOP reduction in patients with NVG than POAG. They suggested that, this could be related to the higher preoperative IOP in NVG patients than OAG participants and to the different exposure time of the ultrasound utilized as well as the small sample number of the included NVG.

We employed the 2nd generation probe in the current study with its noticeable advantages over its antecedent. The size of the transducer had increased from 2.5 mm in the 1st generation probe to 4 mm. The increased size allows wider treatment zone, thus abolishing the influence of the possible anatomical variations of the ciliary body. Higher success rate (67%) was reported by Rouland and Apte[10] utilizing the 2nd generation probe with a mean IOP reduction of 44% in these patients. Giannaccare et al[14] showed that the second-generation probes resulted in a highly statically significant IOP reduction (P<0.05). Denis[15] conducted a metanalysis study aiming mainly at comparing the efficacy of the two generations of the probe and found that at 6-month post therapy, the 2nd generation probe achieved higher mean IOP reduction (35%) compared to 29% by its comparator.
Regarding the exposure time, favorable IOP control was achieved with longer exposure time in a study conducted by Denis et al.\textsuperscript{[12]} comparing 6s vs 4s treatment. The 8s exposure protocol standard with the 2\textsuperscript{nd} generation probe was proved to be superior to the 1\textsuperscript{st} generation treatments with shorter exposure times (4 and 6s)\textsuperscript{[7,18-19]}. Furthermore; Deb-Joardar and Reddy\textsuperscript{[13]} compared more prolonged protocols of 8 and 10s. Though insignificant difference in IOP reduction was noticed (45\% with 8s vs 41\% with 10s); patients with 10s protocol experienced higher incidence of scleral marks and anterior chamber reaction.

In our study, we did not record any major complications either during the procedure or along the follow-up period. Particularly, severe hypotony or phthisis, which are commonly reported following most of the known cyclodestructive procedures\textsuperscript{[20-22]}. No records for IOP spikes or significant IOP rise either in the early or all over the follow up period. Clinical examinations reported moderate signs of intraocular inflammation without hypopyon or synchia as signs of severe inflammation. Punctate keratitis encountered in the study was supposed to be due to mechanical effect caused by the suction cone during its placing. Visual acuity remained statistically unchanged at the last follow-up. These signs of well tolerability of the UCP was compatible with previous studies\textsuperscript{[8-10]}. The retrospective nature of the study with the relatively small sample size represent the limitations of the study. However, widening our inclusion categories to include angle-closure as well as secondary glaucoma naïve to surgery with long term follow-up constitute points of strength to our current study. Further prospective randomized comparative studies are required to prove the superiority of this modality over standard cyclodestructive procedures as diode CPC.

The present study shows that UCP using 2\textsuperscript{nd} generation high-intensity focused ultrasound using 8s protocol proved to be effective in reducing IOP in non-refractory glaucoma patients. However, lower efficacy seems to occur with cases of neovascular and uveitic glaucoma.

**ACKNOWLEDGEMENTS**

**Authors’ contributions:** Torky MA and Al Zafiri YA were responsible for the design, surgical treatment and data collection. Torky MA and Hagras SM participated in the interpretation of the data and wrote the first draft of the manuscript. Hagras SM worked on the statistical analysis. Torky MA and Mokbel TH shared in intellectual content of the draft. Torky MA, Khattab AM and Bassiony RM shared in revising the manuscript. All the authors perused and approved the final manuscript version that was submitted for publication.

**Conflicts of Interest:** Torky MA, None; Al Zafiri YA, None; Hagras SM, None; Khattab AM, None; Bassiony RM, None; Mokbel TH, None.

**REFERENCES**


15 Rouland JF, Aptel F. Primary open angle glaucoma treated by high intensity focused ultrasound (HIFU): results at 18mo of a prospective pilot study on patients treated with the 2nd generation probe. Acta Ophthalmol 2016;94.


